View all news
March 30, 2010

Ironwood Pharmaceuticals Files Annual Report on Form 10-K

CAMBRIDGE, Mass., Mar 30, 2010 (BUSINESS WIRE) -- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today filed its Annual Report on Form 10-K for the year ended December 31, 2009 with the U.S. Securities and Exchange Commission. The report is available on the Investors section of Ironwood's website at In addition, any Ironwood stockholder can request a printed copy of the annual report free of charge by contacting Investor Relations at +1.617.621.8304 or

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's first-in-class GC-C agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass.

SOURCE: Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.
Susan Brady, 617-621-8304
Corporate Communications

Copyright Business Wire 2010

Categories: Press Releases
View all news